Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Biotech Takes Electrifying Approach To Developing An HIV Vaccine

  • News

Executive Summary

In the tumultuous quest to create an effective HIV vaccine, an approach that combines a DNA vaccine with a jolt of electricity looks to be a promising candidate in monkeys, but more data is needed in humans before breaking out the champagne, researchers say

You may also be interested in...



HIV Vaccine Work Awaits Next STEP In Merck Analysis; Failure Aids Biomarker

Plans for PAVE 100, the National Institute on Allergy and Infectious Diseases' Phase IIb HIV vaccine study, remain on hold until the next wave of Merck's STEP data - also expected to aid preclinical vaccine development - is released, researchers say

Merck, NIH Cannot Explain Higher Number Of AIDS Cases In HIV Vaccinated Individuals

In some instances, the vaccine may have led to an increase in HIV infections.

Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales

Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By